

INFORMATION DISCLOSURE STATEMENT

Applicant	: Ekberg et al.
App. No	: 10/575,701
Filed	: April 12, 2006
For	: THERAPEUTIC APPLICATIONS FOR C-PEPTIDE
Examiner	: Unknown
Art Unit	: Unknown

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 15 references to be considered by the Examiner. Also enclosed are 15 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement. Please note that the relevance of the foreign-language references is that they were considered during the drafting of the priority application.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: December 8, 2006

By: 
Marina L. Gordey
Registration No. 52,950
Agent of Record
Customer No. 20,995
(805) 547-5580

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/575,701
	Filing Date	April 12, 2006
	First Named Inventor	Ekberg et al.
	Art Unit	Unknown
(Multiple sheets used when necessary)	Examiner	Unknown
SHEET 1 OF 2	Attorney Docket No.	FDEHN10.001APC

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	1	EP 0 132 769A1	02-13-1985	Hoechst Aktiengesellschaft		Abstract
	2	WO 98/13384	04-02-1998	Creative Peptides Sweden AB		
	3	SE 460334 B	10-02-1989	Eli Lilly & Co.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	4	HENRIKSSON, M. et al. (2000) "Unordered structure of proinsulin c-peptide in aqueous solution and in the presence of lipid vesicles" <i>Cell. Mol. Life Sci.</i> 57:337-342.	
	5	IDO, Y. et al. (1997) "Prevention of vascular and neural dysfunction of diabetic rats by c-peptide" <i>Science</i> 277:563-566.	
	6	JOHANSSON, J. et al. (2002) "Molecular effects of proinsulin c-peptide" <i>Biochem. Biophys. Res. Com.</i> 295:1035-1040.	
	7	KAMIYA, H. et al. (2004) "C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes" <i>Ann. Neurol.</i> 56:827-835.	
	8	KITAMURA, T. et al. (2001) "Proinsulin c-peptide rapidly stimulates mitogen-activated protein kinases in swiss 3T3 fibroblasts: requirement of protein kinase c, phosphoinositide 3-kinase and pertussis toxin-sensitive g-protein" <i>Biochem. J.</i> 355:123-129.	
	9	PRAMANIK, A. et al. (2001) "C-peptide binding to human cell membranes: importance of glu27" <i>Biochem. Biophys. Res. Com.</i> 284:94-98.	
	10	RIGLER, R. et al. (1999) "Specific binding of proinsulin c-peptide to human cell membranes" <i>PNAS USA</i> 96:13318-13323.	
	11	SHAFQAT, J. et al. (2006) "Proinsulin c-peptide elicits disaggregation of insulin resulting in enhanced physiological insulin effects" <i>Cell. Mol. Life Sci.</i> 63:1805-1811.	
	12	SIMA, A.A.F. et al. (2001) "C-peptide prevents and improves chronic type 1 diabetic polyneuropathy in the bb/wor rat" <i>Diabetologia</i> 44:889-897.	
	13	WAHREN, J. et al. (2000) "Role of c-peptide in human physiology" <i>Am. J. Physiol. Endocrinol. Metab.</i> 278:E-759-E768.	
	14	WAHREN, J. et al. (2003) "Does c-peptide have a role in the pathophysiology of type 1 diabetes?" Chapter 29 in <i>International Textbook of Diabetes</i> , 3 rd Ed. Wiley pub., London.	

Examiner Signature	/Stacey Macfarlane/	Date Considered	06/11/2009
--------------------	---------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a checkmark in the box if the citation is considered relevant to the invention. If the citation is not considered relevant, the box should be lined through. /S.M./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/575,701
	Filing Date	April 12, 2006
	First Named Inventor	Ekberg et al.
	Art Unit	Unknown
(Multiple sheets used when necessary)	Examiner	Unknown
SHEET 2 OF 2	Attorney Docket No.	FDEHN10.001APC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	15	ZHANG, W. et al. (2006) "C-peptide improves neuropathy in type 1 diabetic bb/wor-rats" <i>Diabetes Met. Res. Revs.</i> Epub ahead of print, 9 pages.	

3162699:vr
113006